NEW YORK (GenomeWeb) – Med Fusion and GenomOncology have partnered to provide genomic profiles of patient tumors for treatment guidance and clinical trial enrollment, the companies said today.
Under the agreement, Med Fusion, a clinical service laboratory and clinical trials service organization based in Lewisville, Texas, will combine its solid tumor panels with GenomOncology's GO Clinical Workbench platform, a decision support tool that interprets tumor sequence data and translates molecular profiles into clinical reports.
Med Fusion said it plans to launch several disease-specific solid tumor panels, including for non-small cell lung cancer and colorectal cancer, early in the third quarter.
GenomOncology, located in Cleveland, will use the GO Clinical Workbench to interpret next-generation sequencing data from the tumors, in conjunction with other factors, to create reports and provide rules-based decision support for clinical data interpretation.
"Increased understanding of the underlying genetic changes that may be driving tumor growth or metastasis can enable precise treatment strategies tailored to the genetic profile of each patient's cancer," said Tom Lohmann, chief medical officer of Med Fusion, in a statement.